New analysis in BMJ looks at avoidable excess medicine and waste in top 20 U.S. cancer drugs and how to prevent it
Examining Congressional comments regarding Medicare’s Part B pilot proposal.
An analysis on why proposed changes to the system are being met with opposition and the impact for providers and patients.
In this paper, we discuss the unique features of the market for anticancer drugs and assess trends in the launch prices for 58 anticancer drugs approved between 1995 and 2013 in the United States.
In a Forbes guest post, Dr. Bach responds to Dr. John LaMattina's criticism of a previous post authored by Dr. Bach.
Dr. Bach responds to industry leaders who argue that high prices are necessary for innovation.